1476 related articles for article (PubMed ID: 15180757)
1. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
[TBL] [Abstract][Full Text] [Related]
6. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
7. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
8. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.
Cruz AA; Lima F; Sarinho E; Ayre G; Martin C; Fox H; Cooper PJ
Clin Exp Allergy; 2007 Feb; 37(2):197-207. PubMed ID: 17250692
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
10. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.
Humbert M; Berger W; Rapatz G; Turk F
Allergy; 2008 May; 63(5):592-6. PubMed ID: 18355388
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Chervinsky P; Casale T; Townley R; Tripathy I; Hedgecock S; Fowler-Taylor A; Shen H; Fox H
Ann Allergy Asthma Immunol; 2003 Aug; 91(2):160-7. PubMed ID: 12952110
[TBL] [Abstract][Full Text] [Related]
13. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
14. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
Nowak D
Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab: efficacy in allergic disease.
Spector S
Panminerva Med; 2004 Jun; 46(2):141-8. PubMed ID: 15507883
[TBL] [Abstract][Full Text] [Related]
17. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis.
Humbert M; Boulet LP; Niven RM; Panahloo Z; Blogg M; Ayre G
Allergy; 2009 Jan; 64(1):81-4. PubMed ID: 19076535
[TBL] [Abstract][Full Text] [Related]
19. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
Busse WW; Massanari M; Kianifard F; Geba GP
Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
[TBL] [Abstract][Full Text] [Related]
20. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
Dodig S; Richter D; Cepelak I; Benko B
Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]